Search

Search Constraints

You searched for: Author/Creator Wollner, Mira

Search Results

1. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. (28th January 2022)

2. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. Issue 5 (16th September 2020)

4. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. (December 2018)

8. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. (1st January 2021)

9. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Issue 2 (17th February 2021)